LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access ...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) ...
LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced the initiation of an Expanded Access Program (EAP) for molgramostim, ...
As the premiere networking event in the presenting, booking, and touring field, APAP|NYC+ 2023 offers unparalleled opportunities for performing arts professionals to connect with peers; form fresh ...
Program Enables Physicians to Request Molgramostim for Eligible Patients in Select Geographies Where the Product is Not Commercially Available and in Compliance with Local Regulatory Requirements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback